| pubmed-article:16167527 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0019004 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0332174 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C1522484 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0036525 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C1704410 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0205170 | lld:lifeskim |
| pubmed-article:16167527 | lifeskim:mentions | umls-concept:C0205191 | lld:lifeskim |
| pubmed-article:16167527 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:16167527 | pubmed:dateCreated | 2005-9-19 | lld:pubmed |
| pubmed-article:16167527 | pubmed:abstractText | Pharmacokinetic properties of many antineoplastic agents or their metabolites change with organ dysfunction. Unfortunately, chemotherapy doses determined in phase I and II studies in patients with normal hepatic and renal reserves are not usually applicable to those with hepatic and/or renal dysfunction. Considering the high incidence of colorectal adenocarcinoma, it is not unusual for a colorectal cancer patient to be on chronic hemodialysis. We report a patient with metastatic colorectal cancer on chronic hemodialysis who tolerated weekly irinotecan at 50 mg/m2 well without significant toxicity. We briefly discuss therapeutic dose modification in such patients. | lld:pubmed |
| pubmed-article:16167527 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16167527 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16167527 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16167527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16167527 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16167527 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16167527 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:16167527 | pubmed:issn | 1120-009X | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:YildirimNN | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:ZenginNN | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:AbaliHH | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:OksüzogluBB | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:BudakogluBB | lld:pubmed |
| pubmed-article:16167527 | pubmed:author | pubmed-author:UncuDD | lld:pubmed |
| pubmed-article:16167527 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16167527 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:16167527 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16167527 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16167527 | pubmed:pagination | 452-3 | lld:pubmed |
| pubmed-article:16167527 | pubmed:dateRevised | 2009-8-4 | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:meshHeading | pubmed-meshheading:16167527... | lld:pubmed |
| pubmed-article:16167527 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:16167527 | pubmed:articleTitle | Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis. | lld:pubmed |
| pubmed-article:16167527 | pubmed:affiliation | Ankara Numune Egitim ve Aractirma Hastanesi, Tlbbi Onkoloji Klinigi, Ankara, Turkey. burbudak@hotmail.com | lld:pubmed |
| pubmed-article:16167527 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16167527 | pubmed:publicationType | Case Reports | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16167527 | lld:pubmed |
